Difference between revisions of "Postema EJ, et al. J. Nucl. Med. (2003) cited as Ref 553 in DOI: 10.1038/s41392-020-0110-5 (Q9816)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 44, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: title (P93): Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer, #quickstatements; #temporary_batch_1590010982689) |
||
| Property / title | |||
| + | Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer (English) | ||
| Property / title: Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer (English) / rank | |||
| + | Normal rank | ||
Revision as of 22:04, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Postema EJ, et al. J. Nucl. Med. (2003) cited as Ref 553 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Postema EJ
0 references
2003
0 references
J. Nucl. Med.
0 references
44
0 references
Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer (English)
0 references
